Al Batran, S.-E., Hofheinz, R.D., et al. (2016) Histopathological Regression after Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-Label, Randomised Phase 2/3 Trial. Lancet Oncology, 17, 1697-1708.
https://doi.org/10.1016/S1470-2045(16)30531-9

has been cited by the following article:

• TITLE: Perioperative Treatment in Gastric Cancer—Developments in Patient Selection

  AUTHORS: Manuela Machado, Helena Magalhães, Mário Fontes-Sousa

  KEYWORDS: Gastric Cancer, Perioperative Chemotherapy, Molecular Classification of Gastric Cancer, MSI

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.2, February 2, 2018

  ABSTRACT: Gastric cancer (GC) is a major public health issue. It is considered the 5th most common cancer diagnosed worldwide and it is one of the main causes of malignant disease-associated morbidity and mortality. The cornerstone of curative treatment is still surgery, and since the rate of relapse is high, a multidisciplinary approach is warranted in most developed countries. And while there have been recent developments in the perioperative scenario namely the FLOT regimen, little has advanced considering patient selection. We have reviewed the major trials in this setting and provide some insights from recently reported microsatellite instability (MSI) in a subgroup analysis in the MAGIC trial patients that seem to suggest an opportunity to patient selection. Furthermore, GC subtyping may prove helpful selecting candidates to immunotherapy or even multimodal therapy in the future. As the paradigm is moving towards a precision oncology model, GC patient selection remains one the biggest challenges in oncology but seems closer to clinical practice reality as new developments are being reported.